Attila Lenkey
Pulmonary Disease · Wheeling, WVNPI 1720170947
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.8% of the total across 71 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by AstraZeneca at 25.9% of the total. Reporting peaked in 2023 at $643 and has fallen 87.5% since, to $80 in 2024.
Across 71 payments — averaging $24.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$452
- Boehringer Ingelheim$164
- Jazz Pharmaceuticals Inc.$143
- Novo Nordisk$125
- Amgen$122
- Inspire Medical Systems, Inc.$109
- plus $632 from 16 others
What the payments were for
- Food & beverage$1,60592%
- Education$1438%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 26 | $452 |
| Boehringer Ingelheim | 6 | $164 |
| Jazz Pharmaceuticals Inc. | 3 | $143 |
| Novo Nordisk | 1 | $125 |
| Amgen | 6 | $122 |
| Inspire Medical Systems, Inc. | 1 | $109 |
| Axsome Therapeutics, Inc. | 5 | $94 |
| GSK | 4 | $73 |
| Johnson & Johnson | 1 | $66 |
| Novartis | 1 | $50 |
| Harmony Biosciences LLC | 2 | $46 |
| Actelion Pharmaceuticals US, Inc. | 2 | $43 |
| Merck | 2 | $36 |
| Sanofi | 2 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $33 |
| Genentech USA, Inc. | 2 | $28 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $28 |
| United Therapeutics Corporation | 1 | $28 |
| Grifols USA, LLC | 1 | $26 |
| Mylan Specialty L.p. | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $16 |
| Resmed Corp | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Inspire$109
How this compares
$1,747 in reported general payments places this provider in the 55th percentile of 89 pulmonary disease providers in West Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $31,143 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 26 | $13,884 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 25 | $12,586 |
| SymbicortBudesonide/Formoterol Fumarate | 20 | $8,124 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 79 | $2,036 |
| Ventolin HfaAlbuterol Sulfate | 16 | $1,079 |
| Montelukast Sodium | 36 | $502 |
| Zolpidem Tartrate | 50 | $326 |
| Gabapentin | 15 | $282 |
| Prednisone | 27 | $98 |
| Temazepam | 18 | $81 |
| Alprazolam | 21 | $67 |
| Fluticasone Propionate | 11 | $45 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta | $73 | $43,72959 claims |
| Boehringer IngelheimStiolto Respimat | $164 | $13,88426 claims |
| AstraZenecaSymbicort | $452 | $8,12420 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 89 pulmonary disease providers in West Virginia.
Other pulmonary disease in Wheeling
- Kourtney KingWheeling$8K
- Lyndave Francis FrankWheeling$544
- Melvin SaludesGlen Dale$255K
- Roger AbrahamsMorgantown$133K
- Maria BoustaniBeckley$95K
- Ramzi HaddadinBeckley$43K
- Salam RajjoubBridgeport$29K
- Peter KochupuraMorgantown$22K
- Phillip AguilaMartinsburg$21K
- Ryan WaddellCharleston$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.